Interplay between mutant p53 and PML; implications for tumourigenesis. [ 2008 - 2011 ]

Also known as: How mutation of the anti-cancer protein p53 can affect its partnerships and cause cancer.

Research Grant

[Cite as]

Researchers: Prof Ygal Haupt (Principal investigator)

Brief description The most important agent of the body for fighting cancer is the cellular protein p53. In more than 50% of all human cancers, it looses its anticancer properties through mutation. In an insidious manner this new mutant form then acts to promote cancer. To better treat cancer we need to understand how mutant p53 functions. We will study how it interacts with its molecular partners in cancer cells.

Funding Amount $AUD 483,737.21

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]